Search results for Milatuzumab

Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade, ProteoGenix, PX-TA1095

Description of Milatuzumab Biosimilar - Anti-CD74 mAb - Research Grade Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Milatuzumab Biosimilar – Anti-CD74 mAb – Research Grade Introduction Milatuzumab Biosimilar is a monoclonal antibody (mAb) that targets the CD74 protein. It is a biosimilar version of the original Milatuzumab, which was developed and approved for clinical use in the treatment of B-cell malignancies. The biosimilar version has been designed to have the same structure, activity, and therapeutic potential as the original, but at a more affordable cost for research purposes. Structure Milatuzumab Biosimilar is a humanized IgG1 kappa monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a constant region (Fc) and a variable region (Fab), with the Fab region responsible for binding to the CD74 protein. Activity The main activity of Milatuzumab Biosimilar is its ability to bind to the CD74 protein. CD74 is a cell surface protein that is overexpressed in various types of cancer, including B-cell malignancies. By binding to CD74, Milatuzumab Biosimilar can block its activity and inhibit the growth and survival of cancer cells. It can also trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhance its anti- cancer effects. Application Milatuzumab Biosimilar has a wide range of potential applications in cancer research. It can be used as a tool for studying the role of CD74 in cancer development and progression. It can also be used to screen for potential therapeutic targets and to evaluate the efficacy of novel anti- cancer drugs. Additionally, Milatuzumab Biosimilar can be used in pre-clinical studies to assess its potential as a therapeutic agent for B-cell malignancies and other CD74-expressing cancers. Therapeutic Target The main therapeutic target of Milatuzumab Biosimilar is the CD74 protein. CD74 is a transmembrane protein that is involved in various cellular processes, including immune response, cell proliferation, and survival. It is overexpressed in many types of cancer and has been identified as a potential therapeutic target for cancer treatment. By targeting CD74, Milatuzumab Biosimilar can disrupt the signaling pathways that promote cancer cell growth and survival, leading to tumor regression and improved patient outcomes. Conclusion Milatuzumab Biosimilar is a promising research tool for studying the role of CD74 in cancer and evaluating its potential as a therapeutic target. Its similar structure and activity to the original Milatuzumab make it a cost-effective option for pre-clinical studies. With its ability to inhibit cancer cell growth and trigger immune-mediated cytotoxicity, Milatuzumab Biosimilar has the potential to be a valuable addition to the arsenal of anti- cancer therapies.

Milatuzumab, Kyinno, KB-1193

Milatuzumab, Abbexa, abx831052

Milatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD74, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.

Milatuzumab ELISA Kit, ProteoGenix, KPTX143

Description of Milatuzumab ELISA Kit Introduction Milatuzumab is a humanized monoclonal antibody that targets the CD74 receptor, a protein that is overexpressed in various types of cancer cells. This antibody has shown promising results in pre-clinical and clinical studies, making it a potential therapeutic target for cancer treatment. The Milatuzumab ELISA Kit is a valuable tool for detecting and quantifying this antibody in biological samples, providing researchers with important insights into its structure, activity, and potential applications. Structure of Milatuzumab Milatuzumab is a chimeric IgG1 antibody, meaning it contains both human and mouse components. It consists of two heavy chains and two light chains, each with a unique amino acid sequence that determines its binding specificity. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The VH and VL domains come together to form the antigen-binding site, which recognizes and binds to the CD74 receptor. Activity of Milatuzumab The main mechanism of action of Milatuzumab is through its binding to the CD74 receptor, which is found on the surface of cancer cells. This binding blocks the interaction between CD74 and its ligand, MIF, leading to the inhibition of downstream signaling pathways that promote cancer cell survival and proliferation. In addition, Milatuzumab can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further contribute to its anti-tumor activity. Applications of Milatuzumab ELISA Kit The Milatuzumab ELISA Kit is a highly sensitive and specific assay that allows for the measurement of Milatuzumab levels in various biological samples, such as serum, plasma, and cell culture supernatants. This kit is useful for both pre-clinical and clinical studies, providing researchers with valuable information on the pharmacokinetics and pharmacodynamics of Milatuzumab. It can also be used to monitor the efficacy of Milatuzumab treatment in patients, as well as to assess the potential for drug-drug interactions. Detection of Milatuzumab in Cancer Patients The Milatuzumab ELISA Kit has been used in several clinical studies to detect and quantify Milatuzumab levels in cancer patients. In a phase I clinical trial, the kit was used to measure Milatuzumab levels in the serum of patients with advanced solid tumors, and it was found that Milatuzumab had a half-life of approximately 10 days. In another study, the kit was used to monitor Milatuzumab levels in the serum of patients with multiple myeloma, and it was found that higher levels of Milatuzumab were associated with better clinical outcomes. Conclusion In summary, the Milatuzumab ELISA Kit is a valuable tool for detecting and quantifying Milatuzumab, a promising therapeutic antibody that targets the CD74 receptor. Its structure, activity, and applications make it a promising candidate for cancer treatment, and the Milatuzumab ELISA Kit provides researchers with important insights into its pharmacokinetics and pharmacodynamics. Further studies and clinical trials are needed to fully understand the potential of Milatuzumab as a therapeutic target for cancer.

Milatuzumab ELISA Kit, Abbexa, abx395032

Milatuzumab ELISA Kit is a quantitative ELISA kit for detection of Milatuzumab.Milatuzumab is a new immunotherapeutic agent targeting CD74, a membrane protein preferentially expressed in hematopoietic cancers and some solid tumors. Broad expression and fast internalization makes CD74 an ideal target for cancer therapy. We reviewed published articles about CD74 and milatuzumab. We present a comprehensive review of CD74 functions and provide explanation of milatuzumab antitumor effects. This review describes CD74 protein biology with the emphasis on the role of CD74 in tumor survival and its new role in regulation of the Fas death receptor. The development of CD74 targeting therapies to induce tumor regression and cancer cell apoptosis is described and results of clinical trials are discussed. Milatuzumab shows selective binding and rapid internalization into CD74-positive cancer cells. Milatuzumab with and without conjugated toxins synergizes with other chemotherapeutic agents and elicits significant antitumor effects in mice. In a Phase I trial, milatuzumab showed no severe adverse effects in patients with relapsed/refractory multiple myeloma and it stabilized the disease in some patients for up to 12 weeks. Ongoing trials testing different treatment schedules of milatuzumab in chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma indicate that milatuzumab shows no severe adverse effects in humans.

Milatuzumab Biosimilar - Research Grade, ichor.bio, ICH5681

Research Grade Milatuzumab (HY465016), abinScience, HY465016